Compound containing basic group and use thereof

Details Compound containing basic group and use thereof Compound containing basic group and use thereof

2011-05-31

2011-05-31

Jarrell, Noble (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S016000

Reexamination Certificate

active

07951816

ABSTRACT:
The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

REFERENCES:
patent: 3301857 (1967-01-01), Berger et al.
patent: 5962462 (1999-10-01), Mills et al.
patent: 6291469 (2001-09-01), Fisher et al.
patent: 7176227 (2007-02-01), Yamazaki et al.
patent: 2002/0018124 (2002-02-01), Mottur et al.
patent: 2003/0018046 (2003-01-01), Bridger et al.
patent: 2003/0187023 (2003-10-01), Kubo et al.
patent: 2003/0220341 (2003-11-01), Bridger et al.
patent: 2004/0019058 (2004-01-01), Bridger et al.
patent: 2004/0254221 (2004-12-01), Yamazaki et al.
patent: 2005/0165063 (2005-07-01), Yamazaki et al.
patent: 2007/0208007 (2007-09-01), Saitou
patent: 2007/0208033 (2007-09-01), Yamazaki et al.
patent: 2008/0009495 (2008-01-01), Kokuto et al.
patent: 2009/0169567 (2009-07-01), Kokubo et al.
patent: 2009/0192182 (2009-07-01), Kusumi et al.
patent: 0070171 (1983-01-01), None
patent: 1308439 (2003-05-01), None
patent: 1378510 (2004-01-01), None
patent: 1724263 (2006-11-01), None
patent: 49-013184 (1974-02-01), None
patent: 49-072332 (1974-07-01), None
patent: 04-018092 (1992-01-01), None
patent: 11321508 (1999-11-01), None
patent: 2002-348288 (2002-12-01), None
patent: 2003-0104884 (2003-04-01), None
patent: 2004-508421 (2004-03-01), None
patent: 2004-508422 (2004-03-01), None
patent: 2005-518397 (2005-06-01), None
patent: 95/01358 (1995-01-01), None
patent: 97/11940 (1997-04-01), None
patent: 98/25605 (1998-06-01), None
patent: 01/13917 (2001-03-01), None
patent: 2002/022599 (2002-03-01), None
patent: 2002/022600 (2002-03-01), None
patent: WO 02/22600 (2002-03-01), None
patent: 02/074770 (2002-09-01), None
patent: 03/020721 (2003-03-01), None
patent: 03/024941 (2003-03-01), None
patent: 03/029218 (2003-04-01), None
patent: WO 03/029218 (2003-04-01), None
patent: 03/055876 (2003-07-01), None
patent: 03/057698 (2003-07-01), None
patent: WO 03/055876 (2003-07-01), None
patent: 2004/024697 (2004-03-01), None
patent: WO 2004/024697 (2004-03-01), None
patent: 2005/085209 (2005-09-01), None
patent: 2006/022454 (2006-03-01), None
U.S. Appl. No. 12/332,716, filed Dec. 2008, Nishizawa et al.
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Jantzen and Robinson. Modern Pharmaceutics, 1996, p. 596.
Soto et al. Basic Immunology, 2008, 68, 43-57.
“Rheumatoid arthritis-prevention”, http://www.webmd.com/rheumatoid-arthritis/tc/rheumatoid-arthritis-prevention, accessed Aug. 28, 2009.
Mosley et al. Expert Opinion on Therapeutic Patents, 2009, 19(1), 23-28.
Burger et al. Expert Opinion on Investigative Drugs, 2009, 18(4), 481-90.
“Cancer definition”, http://www.medterms.com/script/main/art.asp?articlekey=2580, accessed Nov. 27, 2007.
Agarwal et al. Expert Opinion on Drug Discovery, 2009, 4(2), 147-158.
Pease et al. Expert Opinion on Therapeutic Patents, 2009, 19(2), 199-221.
Mehrad et al. The International Journal of Biochemistry and Cell Biology, 2009, 41, 1708-18.
Tamamura. Expert Opinion on Drug Discovery, 2008, 3(10), 1155-66.
“Arthritis-types of arthritis”, http://www.webmd.com/osteoarthritis/guide/arthritis-basics, accessed Apr. 26, 2010.
Link et al. Arthritis Research, 2001, 4, 80-83.
Extended European Search Report issued in Application No.: 05776646.1, dated Aug. 10, 2010.
Borna Mehrad, et al., “Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis”, The International Journal of Biochemistry & Cell Biology, 2009, pp. 1708-1718, vol. 41.
Cara A. Mosley, et al., “Recent patents regarding the discovery of small molecule CXCR4 antagonists” Expert Opin. Ther. Patents, 2009, pp. 23-38, vol. 19, No. 1.
Christopher A. Lipinski, “Section VI—Topics in Chemistry and Drug Design”, Annual Reports in Medicinal Chemistry, 1986, pp. 283-291, vol. 21.
H. Soto, et al., “Gene Array Analysis Comparison between Rat Collagen-induced Arthritis and Human Rheumatoid Arthritis”, Scandinavian Journal of Immunology, 2008, pp. 43-57, vol. 68.
Hirokazu Tamamura et al., “A future perspective on the development of chemokine receptor CXCR4 antagonists”, Expert Opin. Drug Discov., 2008, pp. 1155-1166, vol. 3, No. 10.
James E. Pease, et al., “Chemokine receptor antagonists: part 2”, Expert Opin Ther. Patents, 2009, pp. 199-221, vol. 19, No. 2.
Jan A. Burger, et al., “CXCR4 chemokine receptor antagonists: perspectives in SCLC”, Expert Opin. Investig. Drugs, 2009, 481-490, vol. 18, No. 4.
Jantzen et al., “Modern Pharmaceutics”, 1996, p. 596.
Jason M. Link, et al., “Clues to the etiology of autoimmune diseases through analysis of immunoglobulin genes”, Arthritis Research, 2002, pp. 80-83, vol. 40, No. 2.
Paul W. Smith, et al., “New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK2 Receptor Antagonists”, J. Med. Chem., 1995, pp. 3772-3779, vol. 38, XP009135475.
Renu Agarwal, et al., “Therapeutic potential of Curcuma longa, the golden spice of India, in drug discovery for ophthalmic diseases”, Expert Opin. Drug Discov., 2009, pp. 147-158, vol. 4, No. 2.
Sudha R. Vippagunta, et al., “Crystalline solids”, Advanced Drug Delivery Reviews, 2001, pp. 3-26, vol. 48.
Tara Mirzadegan, et al., “Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists”, The Journal of Biological Chemistry, 2000, pp. 25562-25571, vol. 275, No. 33.
Extended European Search Report issued May 29, 2009 in European Application No. 06832893.9, counterpart of U.S. Appl. No. 12/094,100.
Supplementary European Search Report issued Jul. 9, 2010 in European Application No. 047279985.6 counterpart of U.S. Appl. No. 12/332,716.
International Search Report for PCT/JP04/005493 corresponding to (parent) U.S. Appl. No. 10/553,596 dated Aug. 3, 2004.
Arthritis Basics; http://www.webmed.com/osteoarthritis/guide/arthritis-basic, retrieved Apr. 26, 2010, pp. 1-4.
Definition of Cancer; Medicine Net.com; http://www.medterms.com/script/main/art.asp?articlekey=(1 of 3), retrieved Nov. 27, 2007, pp. 1-3.
Rheumatoid Arthritis—Prevention, http://www.webmed.com/rheumatoid-arthritis/tc/rheumatoid-arthritis-prevention, retrieved Aug. 28, 2009, pp. 1-3.
American Cancer Society, “Can Cancer Be Prevented?”; http://www.cancer.org/docroot/CRI/content/CRI—2—4—2x—Can—cancer—be—prevented.asp, retrieved May 27, 2010, p. 1.
TeensHealth, “HIV and AIDS,” http://kidshealth.org/teen/infections/stds/std—hiv.html, retrieved May 27, 2010, pp. 1-3.
CA 1983:470751. See CA registry #85732-34-9 and CA registry #85732-35-0.
CA 1984:510946. See CA registry #85732-35-0 and CA registry #85732-42-9.
CA 1989:407312. See CA registry #85732-35-0 and CA registry #121061-07-2.
CA 2003:282402. See CA registry #508240-62-8 and CA registry #508240-61-7.
CA 2003:991516. See CA registry #635713-68-7 and CA registry #635713-67-6.

Affiliated with

Also associated with

Rating

Compound containing basic group and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound containing basic group and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound containing basic group and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694933